Direct comparison
IRB vs. IBC: What's the Difference?
IRB reviews human-subjects risk under the Common Rule; IBC reviews rDNA biosafety under NIH Guidelines. Compared side by side, plus when a study needs both.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about IRB vs. IBC: What's the Difference?
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do IRB, IBC compare side by side?
The table below compares IRB, IBC across 7 procurement-relevant dimensions, from what it protects through institution-wide trigger.
Side-by-side comparison
| Dimension | IRB | IBC |
|---|---|---|
| What it protects | Rights and welfare of human research subjects | Lab workers, community, and environment from biohazards |
| Regulatory basis | Common Rule (45 CFR 46); 21 CFR Part 56 for FDA-regulated research | NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules |
| Administering federal office | HHS Office for Human Research Protections (OHRP); FDA for regulated products | NIH Office of Science Policy (OSP) |
| What triggers review | Research (45 CFR 46.102(l)) involving a human subject (45 CFR 46.102(e)) — both conditions required | Use of recombinant/synthetic nucleic acid molecules; most institutions also cover other biohazards by local policy |
| Minimum composition | Majority present at convened meeting, including at least one non-scientist member | At least 5 members with rDNA/containment expertise, including at least 2 unaffiliated community representatives |
| What approval authorizes | Enrollment of human subjects under an approved protocol and consent process | Specific biosafety-level (BSL) procedures under an approved risk-category review |
| Institution-wide trigger | Registration and FWA required per institution operating an IRB for covered research | Once any NIH funding applies to rDNA research, Guidelines apply institution-wide to ALL rDNA work regardless of individual project funding |
Common questions
Common questions about IRB vs IBC
Can the same study need only one of the two committees?
+
Yes. Most studies trigger only one — a survey study needs only IRB review, a non-human bench rDNA experiment needs only IBC review. Overlap arises only when a protocol independently meets both committees' triggers.
Does IBC review require the specific project to be NIH-funded?
+
No. Once an institution receives any NIH funding for recombinant/synthetic nucleic acid molecule research, the NIH Guidelines and IBC review apply institution-wide to all such research, regardless of that project's own funding source.
Which committee assigns the biosafety level?
+
The IBC, through risk-category review of the specific agent, procedure, and volume — not the IRB, even on studies that also require IRB approval.
Is an IBC the same thing as an IACUC?
+
No. An Institutional Animal Care and Use Committee (IACUC) reviews the welfare of live vertebrate animals used in research, under a different statutory basis (the Animal Welfare Act and PHS Policy). A study can require IACUC and IBC review together — for example, an animal study using a recombinant viral vector — on the same logic that a human study can require IRB and IBC review together.
